Irish Journal of Medical Science

, Volume 176, Issue 2, pp 105–109

Incidence and significance of the JAK2 V617F mutation in patients with chronic myeloproliferative disorders

  • S. E. Langabeer
  • F. Ni Ainle
  • E. Conneally
  • M. Lawler
Original Article

Abstract

Background

The chronic myeloproliferative disorders (MPD) are clonal haemopoietic stem cell disorders.

Aims

The incidence of JAK2 V617F mutation was sought in a population of patients with MPD.

Methods

The JAK2 V617 mutation status was determined in 79 patients with known MPD and 59 patients with features suggestive of MPD.

Results

The mutation was found in patients with polycythaemia vera, essential thrombocythaemia, idiopathic myelofibrosis and in patients with other chronic myeloproliferative disorders. Eight JAK2 V617F positive cases were identified amongst those patients with features suggestive of MPD.

Conclusions

The incidence of the JAK2 V617F mutation in MPD patients is similar to that reported by other groups. The assay confirmed and refined the diagnosis of several patients with features indicative of MPD. We suggest screening for this mutation in all patients with known and suspected MPD as identification is valuable in classification and is a potential target for signal transduction therapy.

Keywords

Essential thrombocythaemia Idiopathic myelofibrosis JAK2 V617F Myeloproliferative disorders Polycythaemia vera Tyrosine kinase 

Copyright information

© Royal Academy of Medicine in Ireland 2007

Authors and Affiliations

  • S. E. Langabeer
    • 1
  • F. Ni Ainle
    • 2
  • E. Conneally
    • 2
  • M. Lawler
    • 1
    • 3
  1. 1.Cancer Molecular Diagnostics, Central Pathology LaboratorySt. James’s HospitalDublin 8Ireland
  2. 2.Department of HaematologySt. James’s HospitalDublinIreland
  3. 3.Institute of Molecular MedicineSt. James’s Hospital and Trinity College DublinDublinIreland

Personalised recommendations